Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib Plus Temozolomide in mCRPC Without DNA Damage Repair Mutations
NCT04019327Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2019
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of talazoparib, temozolomide in castration-resistant prostate cancer (CRPC), sponsored by Memorial Sloan Kettering Cancer Center. Started Jul 2019; status: terminated.
02
Drugs
talazoparibtemozolomide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT04019327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04019327.